论文部分内容阅读
目的:评价左氧氟沙星与大剂量氨溴索联用治疗肺癌患者医院感染的临床疗效与安全性。方法:选取2014年1月—2016年1月收治的伴有医院感染的肺癌患者36例,将其分为对照组18例和治疗组18例;对照组患者均给予左氧氟沙星与小剂量氨溴索治疗,治疗组患者均给予左氧氟沙星与大剂量氨溴索治疗,比较两组患者治疗1周后的总有效率与安全性。结果:治疗后,两组患者血气指标均优于治疗前(P<0.05);治疗组患者治疗后血气指标提高幅度明显大于对照组,其总有效率为88.89%高于对照组为77.78%(P<0.05)。结论:采用左氧氟沙星与大剂量氨溴索治疗肺癌患者医院感染,能有效提高抗菌药物治疗的血药浓度,从而使治疗效果最大化。
Objective: To evaluate the clinical efficacy and safety of levofloxacin and high-dose ambroxol in the treatment of nosocomial infections in patients with lung cancer. Methods: Thirty-six patients with lung cancer with nosocomial infection admitted from January 2014 to January 2016 were selected and divided into control group (18 cases) and treatment group (18 cases). Patients in the control group were given levofloxacin and low dose ambroxol Treatment, treatment group were given levofloxacin and high-dose ambroxol treatment, the two groups were compared for 1 week after treatment, the total efficiency and safety. Results: After treatment, the blood gas indexes of both groups were better than those before treatment (P <0.05). After treatment, the improvement rate of blood gas in treatment group was obviously higher than that in control group, the total effective rate was 88.89% and 77.78% P <0.05). Conclusion: Levofloxacin and high-dose ambroxol in the treatment of nosocomial infections in patients with lung cancer can effectively improve the plasma concentration of antibacterial drugs, so that the treatment effect is maximized.